OR WAIT 15 SECS
The new facility will house the company’s expanding R&D operations.
Adaptimmune Therapeutics, a biopharmaceutical company, has announced plans to expand its R&D operation with investment in a new facility at Milton Park, Oxfordshire, United Kingdom.
Construction of Adaptimmune’s 67,000 square foot ‘Enterprise Zone’ building is already under way. The facility will provide laboratory space with associated offices and meeting rooms to accommodate a team of approximately 200 R&D specialists. The new building is designed to support the company’s continuing R&D growth and is scheduled for launch in late 2016.
Adaptimmune has signed a 25-year agreement with break options to lease the building from developer MEPC, which owns Milton Park, one of Europe’s largest business parks and home to over 7500 employees and 250 organizations.
Established in the UK, Adaptimmune launched operations in the United States in 2011 after a long-standing research collaboration with the University of Pennsylvania. The company has rapidly expanded its clinical programs and is currently running five Phase I/II trials in multiple cancers across the US, targeting the NY-ESO-1 cancer antigen in both solid and hematologic cancers with promising early results. Adaptimmune also has an IND open with its second therapeutic candidate, MAGE-A10, and a third candidate in planning for IND submission in 2016.
In May 2015, the company achieved a successful IPO on NASDAQ, generating net proceeds in excess of $176 million, and is advancing a pipeline of therapeutic candidates based on its proprietary T-cell engineering platform.